Skip to main content
OpenTrials
Completed

NCT Number: NCT03521895

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies

The aim of this integrated analysis is to describe the effectiveness of Eylea in an integrated pooled analysis using existing individual patient data of two non-interventional studies RAINBOW and PERSEUS.

The primary objective of this integrated analysis is to describe the effectiveness of Eylea on the mean change from baseline in visual acuity (VA) at 12 months in Wet age-related macular degeneration (wAMD) treatment naïve patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Macular Degeneration Eye Diseases Retinal Degeneration Retinal Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Many locations

Multiple Locations, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

PERSEUS

  • Patients with wet AMD treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC)
  • Documentation of at least one Aflibercept (Eylea) injection
  • Assessment of at least one visual acuity measurement with available VA letter score for the study eye at baseline and at least one post-baseline assessment of visual acuity with available VA letter score for the study eye and valid for analysis, i.e. measured at least 5 days after an injection RAINBOW
  • Patient with a diagnosis of wet AMD will be enrolled after the decision for treatment with Aflibercept (Eylea) has been made
  • Patient who meet the local indication criteria for Eylea treatment
  • At least one BCVA after the 1st Eylea injection
  • BCVA at baseline
  • Patient with no history of retinal disease
  • Patient not previously treated with any macular laser or any anti-VEGF intravitreal injections for the study eye (for fellow eye allowed).
  • For patients with both eyes treated, the eye firstly treated at initial visit will be considered as study eye. If both eyes are treated during initial visit, the treated eye with worst Best-Corrected Visual Acuity (BCVA) at M0 will be retained. If the two conditions are similar the study eye is the Right eye by convention
  • Patient with 1st injection of Eylea from 01 January 2014 until 30 April 2015 will be enrolled Exclusion criteria PERSEUS
  • Exclusion criteria as listed in the local SPC
  • Scar, fibrosis, or atrophy involving the center of the fovea in the study eye
  • All patients previously treated with any macular laser or any anti-VEGF intravitreal injections for the study eye will additionally be excluded for this integrated analysis
  • Any concomitant therapy with another agent to treat wet AMD in the study eye RAINBOW
  • Patient who does not meet the local indication criteria for Eylea treatment. Contraindications listed in the SmPCs must be taken into account
  • Patient with another retinal disease: diabetic retinopathy, diabetic macular oedema (DME), myopic choroidal neovascularization, retinal vein occlusion (RVO), central serous chorioretinopathy (CSC), angioid streaks
  • Patient who has previously been treated with any macular laser (laser and/or visudyne/PDT) or any anti-VEGF intravitreal injections for the study eye
  • Patient taking part in an interventional study at the time of enrolment

Treatment and study plan

Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

Drug

Patients observed with regular and irregular treatment course

Primary outcomes

  1. Absolute difference in visual acuity (VA) change from baseline will be calculated for each patient as: VA letter score at month 12 - VA letter score at baseline

    Time frame: At baseline and 12 months

Secondary outcomes

  1. Mean time from diagnosis by the treating physician to start of treatment

    Time frame: At baseline

  2. Proportion of patients gaining 5, 10 or 15 or more letters

    Time frame: At 12 months

  3. Proportion of patients with ≥70 letters VA

    Time frame: At 12 months

  4. Proportion of patients with ≥73 letters VA

    Time frame: At 12 months

  5. Proportion of patients losing 5, 10 or 15 or more letters

    Time frame: At 12 months

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Acronym: GALAXY

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
May 11, 2018
Registry last updated
Jan 10, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.